OJBD  Vol.3 No.3 , September 2013
Cutaneous Manifestations of Sickle Cell Disease
ABSTRACT
Sickle cell disease is an inherited erythrocyte disorder affecting multiple organ systems. As individuals are living well into middle age due to advances in diagnosis and treatment, further disease-related complications are being recognized. This article reviews the cutaneous manifestations of sickle cell disease including leg ulcers and acquired pseudoxanthoma elasticum.

Cite this paper
H. Jones, M. Blinder and M. Anadkat, "Cutaneous Manifestations of Sickle Cell Disease," Open Journal of Blood Diseases, Vol. 3 No. 3, 2013, pp. 94-99. doi: 10.4236/ojbd.2013.33019.
References
[1]   O. Brawley, L. Cornelius, L. Edwards, V. Gamble, B. Green, C. Inturrisi, et al., “NIH Conference Annals of Internal Medicine National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease,” Annals of Internal Medicine, Vol. 148, No. 12, 2008, pp. 932-938. doi:10.7326/0003-4819-148-12-200806170-00220

[2]   M. Bender and W. Hobbs, “Gene Reveiws,” University of Washington, Seattle, 1993.

[3]   J. Herrick, “Peculiar Elongated and Sickle-shaped Red Blood Corpuscles in a Case of Severe Anemia. 1910,” Yale Journal of Biology and Medicine, Vol. 74, No. 3, 2001, pp. 179-184.

[4]   C. Cummer and C. LaRocco, “Ulcers of the Legs in Sickle Cell Anemia,” Archives of Dermatology, Vol. 42, No. 6, 1940, pp. 1015-1039. doi:10.1001/archderm.1940.01490180024002

[5]   V. Nolan, A. Adewoye, C. Baldwin, L. Wang, D. Wyszzynski, J. Farrell, et al., “Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-B/BMP Pathway,” British Journal of Haematology, Vol. 133, No. 5, 2006, pp. 570-578. doi:10.1111/j.1365-2141.2006.06074.x

[6]   J. Trent and R. Kirsner, “Leg Ulcers in Sickle Cell Disease,” Advances in Skin & Wound Care, Vol. 17, No. 8, pp. 410-416. doi:10.1097/00129334-200410000-00010

[7]   F. Wolfort and T. Krizek, “Skin Ulceration in Sickle Cell Anemia,” Plastic and Reconstructive Surgery, Vol. 43, No. 1, 1969, pp. 71-77. doi:10.1097/00006534-196901000-00011

[8]   E. Chirico and V. Pialoux, “Role of Oxidative Stress in the Pathogenesis of Sickle Cell Disease,” IUBMB Life, Vol. 64, No. 1, 2012, pp. 72-80. doi:10.1002/iub.584

[9]   K. Wood, L. Hsu and M. Gladwin, “Sickle Cell Disease Vasculopathy: A State of Nitric Oxide Resistance,” Free Radical Biology & Medicine, Vol. 44, No. 8, 2008, pp. 1506-1528. doi:10.1016/j.freeradbiomed.2008.01.008

[10]   M. Koshy, R. Entsuah, A. Koranda, A. Kraus, R. Johnson, R. Bellvue, et al., “Leg Ulcers in Patients with Sickle Cell Disease,” Blood, Vol. 74, No. 4, 1989, pp. 1403-1408.

[11]   M. Halabi-Tawil, F. Lionnet, R. Girot, C. Bachmeyer, P. Lévy and S. Aractingi, “Sickle Cell Leg Ulcers: A Frequently Disabling Complication and a Marker of Severity,” British Journal of Dermatology, Vol. 158, No. 2, 2008, pp. 339-344. doi:10.1111/j.1365-2133.2007.08323.x

[12]   G. Serjeant, “Leg Ulceration in Sickle Cell Anemia,” Archives of Internal Medicine, Vol. 133, No. 4, 1974, pp. 690-694. doi:10.1001/archinte.1974.00320160184017

[13]   J. Eckman, “Leg Ulcers in Sickle Cell Disease,” Hematology/Oncology Clinics of North America, Vol. 10, No. 6, 1996, pp. 1333-1344. doi:10.1016/S0889-8588(05)70404-4

[14]   G. Serjeant, B. Serjeant, J. Mohan and A. Clare, “Leg Ulceration in Sickle Cell Disease: Medieval Medicine in a Modern World,” Hematology/Oncology Clinics of North America, Vol. 19, No. 5, 2005, pp. 943-956. doi:10.1016/j.hoc.2005.08.005

[15]   S. Robinson and S. Tasker, “Chronic Leg Ulcers of Sickle Cell Anemia; Report of Case; with Reference to Recognition,” California Western Journal of Medicine, Vol. 64, No. 4, 1946, pp. 250-2.

[16]   S. Sehgal and B. Arunkumar, “Microbial Flora and Its Significance in Pathology of Sickle Cell Disease Leg Ulcers,” Infection, Vol. 20, No. 2, 1992, pp. 86-88. doi:10.1007/BF01711070

[17]   L. McMahon, H. Tamary, M. Askin, P. Adams-Graves, R. Eberhardt, M. Sutton, et al., “A Randomized Phase II Trial of Arginine Butyrate with Standard Local Therapy in Refractory Sickle Cell Leg Ulcers,” British Journal of Haematology, Vol. 15, No. 5, 2010, pp. 516-524. doi:10.1111/j.1365-2141.2010.08395.x

[18]   G. Serjeant, R. Galloway and M. Gueri, “Oral Zinc Sulphate in Sickle-Cell Ulcers,” Lancet, Vol. 31, No. 2, 1970, pp. 891-892. doi:10.1016/S0140-6736(70)92067-2

[19]   R. Ware and B. Aygun. Advances in the Use of Hydroxyurea,” Hematology ASH Education Program, Vol. 2009, No. 1, 2009, pp. 62-69. doi:10.1182/asheducation-2009.1.62

[20]   O. Platt, “Hydroxyurea for the Treatment of Sickle Cell Anemia,” The New England Journal of Medicine, Vol. 358, No. 13, 2008, pp. 1362-1369. doi:10.1056/NEJMct0708272

[21]   M. Gladwin, J. Shelhamer, F. Ognibene, M. Pease-Fye, J. Nichols, B. Link, et al., “Nitric Oxide Donor Properties of Hydroxyurea in Patients with Sickle Cell Disease,” British Journal of Haematology, Vol. 116, No. 2, 2002, pp. 436-444. doi:10.1046/j.1365-2141.2002.03274.x

[22]   R. Khouri and J. Upton, “Bilateral Lower Limb Salvage with Free Flaps in a Patient with Sickle Cell Ulcers,” Annals of Plastic Surgery, Vol. 27, No. 6, 1991, pp. 574-576. doi:10.1097/00000637-199112000-00011

[23]   R. Richards, C. Bowen and M. Glynn. Microsurgical Free Flap Transfer in Sickle Cell Disease,” Annals of Plastic Surgery, Vol. 29, No. 3, 1992, pp. 278-281. doi:10.1097/00000637-199112000-00011

[24]   M. Gueri and G. Serjeant, “Leg Ulcers in Sickle-Cell Anaemia,” Tropical and Geographical Medicine, Vol. 22, No. 2, 1970, pp. 155-160.

[25]   J. Uitto, L. Bervcovitch, S. Terry and P. Terry, “Pseudoxanthoma Elasticum: Progress in Diagnostics and Research towards Treatment: Summary of the 2010 PXE International Research Meeting,” American Journal of Medical Genetics Part A, Vol. 155A, No. 7, 2011, pp. 1517-1526. doi:10.1002/ajmg.a.34067

[26]   W. Geeraets and D. Guerry, “Angioid Streaks and Sickle Cell Disease,” American Journal of Ophthalmology, Vol. 49, 1960, pp. 450-470.

[27]   K. Suerig and F. Siefert, “Pseudoxanthoma Elasticum and Sickle Cell Anemia,” Archives of Internal Medicine, Vol. 113, No. 1, 1964, pp. 135-141. doi:10.1001/archinte.1964.00280070137022

[28]   E. Fabbri, G. Forni, G. Guerrini and C. Borgna-Pignatti, “Pseudoxanthoma-Elasticum-Like Syndrome and Thalassemia: An Update,” Dermatology Online Journal, Vol. 15, No. 7, 2009, p. 7.

[29]   A. Aessopos, P. Savvides, G. Stamatelos, I. Rombos, T. Tassiopoulos, M. Karagiorga, et al., “Pseudoxanthoma Elasticum-Like Skin Lesions and Angioid Streaks in Beta Thalassemia,” American Journal of Hematology, Vol. 41, No. 3, 1992, pp. 159-164. doi:10.1002/ajh.2830410304

[30]   Q. Jiang, M. Endo, F. Dibra, K. Wang and J. Uitto, “Pseudoxanthoma Elasticum Is a Metabolic Disease,” Journal of Investigative Dermatology, Vol. 129, No. 2, 2009, pp. 348-354. doi:10.1038/jid.2008.212

[31]   A. Aessopos, D. Farmakis and D. Loukopoulos, “Elastic Tissue Abnormalities Resembling Pseudoxanthoma Elas- ticum in Beta Thalassemia and the Sickling Syndromes,” Blood, Vol. 99, No. 1, 2002, pp. 30-35. doi:10.1182/blood.V99.1.30

[32]   T. van Meurs, J. van Hagen, M. van de Scheur, H. Vermaat, M. Ruijs, H. van den Hoogenband, et al., “Classic Pseudoxanthoma Elasticum in a Patient with Sickle Cell Disease,” Journal of the American Academy of Dermatology, Vol. 56, No. 1, 2007, pp. 170-171. doi:10.1016/j.jaad.2006.10.023

[33]   A. Adam and M. Maritim, “Pseudoxanthoma Elasticum in a Patient with Sickle Cell Disease: Case Report,” East African Medical Journal, Vol. 85, No. 2, 2008, pp. 98-101. doi:10.4314/eamj.v85i2.9613

[34]   Q. Li, Q. Jiang, E. Pfendner, A. Váradi and J. Uitto, “Pseudoxanthoma Elasticum: Clinical Phenotypes, Molecular Genetics and Putative Pathomechanisms,” Experimental Dermatology, Vol. 18, No. 1, 2009, pp. 1-11. doi:10.1111/j.1600-0625.2008.00795.x

[35]   I. Georgalas, I. Tservakis, D. Papaconstaninou, M. Kardara, C. Koutsandrea and I. Ladas, “Pseudoxanthoma Elasticum, Ocular Manifestations, Complications and Treatment,” Clinical and Experimental Optometry, Vol. 94, No. 2, 2011, pp. 169-80. doi:10.1111/j.1444-0938.2010.00559.x

[36]   E. Cacciola, R. Musso, R. Giustolisi, E. Cacciola and M. Alessi, “Blood Hypercoagulability as a Risk Factor for Leg Ulcers in Sickle Cell Disease,” Blood, Vol. 75, No. 12, 1990, pp. 2467-2478.

 
 
Top